IL195431A0 - Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia - Google Patents

Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia

Info

Publication number
IL195431A0
IL195431A0 IL195431A IL19543108A IL195431A0 IL 195431 A0 IL195431 A0 IL 195431A0 IL 195431 A IL195431 A IL 195431A IL 19543108 A IL19543108 A IL 19543108A IL 195431 A0 IL195431 A0 IL 195431A0
Authority
IL
Israel
Prior art keywords
schizophrenia
alzheimer
pain
disease
effective
Prior art date
Application number
IL195431A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Tomaszewski Miroslaw
Cheng Yun Xing
Pourashraf Mehrnaz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Tomaszewski Miroslaw, Cheng Yun Xing, Pourashraf Mehrnaz filed Critical Astrazeneca Ab
Publication of IL195431A0 publication Critical patent/IL195431A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
IL195431A 2006-06-09 2008-11-20 Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia IL195431A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81220906P 2006-06-09 2006-06-09
PCT/SE2007/000554 WO2007142583A1 (en) 2006-06-09 2007-06-08 Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia.

Publications (1)

Publication Number Publication Date
IL195431A0 true IL195431A0 (en) 2009-08-03

Family

ID=38801727

Family Applications (1)

Application Number Title Priority Date Filing Date
IL195431A IL195431A0 (en) 2006-06-09 2008-11-20 Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia

Country Status (18)

Country Link
US (1) US7956069B2 (OSRAM)
EP (1) EP2035411A1 (OSRAM)
JP (1) JP2009539831A (OSRAM)
KR (1) KR20090018210A (OSRAM)
CN (1) CN101501025A (OSRAM)
AR (1) AR061305A1 (OSRAM)
AU (1) AU2007256012A1 (OSRAM)
BR (1) BRPI0712331A2 (OSRAM)
CA (1) CA2654138A1 (OSRAM)
EC (1) ECSP088966A (OSRAM)
IL (1) IL195431A0 (OSRAM)
MX (1) MX2008015136A (OSRAM)
NO (1) NO20085270L (OSRAM)
RU (1) RU2008147542A (OSRAM)
SA (1) SA07280303B1 (OSRAM)
TW (1) TW200813018A (OSRAM)
UY (1) UY30397A1 (OSRAM)
WO (1) WO2007142583A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200815405A (en) * 2006-06-09 2008-04-01 Astrazeneca Ab Novel compounds
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
UY31672A1 (es) * 2008-02-28 2009-09-30 "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación"
US20090221642A1 (en) * 2008-03-03 2009-09-03 Astrazeneca Ab Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof-176
US20090275574A1 (en) * 2008-05-05 2009-11-05 Astrazeneca Ab Novel compounds-300
GB0817982D0 (en) * 2008-10-01 2008-11-05 Glaxo Group Ltd Compounds
CA2753205A1 (en) * 2009-02-19 2010-08-26 Vanderbilt University Amidobipiperidinecarboxylate m1 allosteric agonists, analogs and derivatives thereof, and methods of making and using same
US20100286124A1 (en) * 2009-04-10 2010-11-11 Auspex Pharmaceuticals, Inc. Prop-2-yn-1-amine inhibitors of monoamine oxidase type b
CN103068798A (zh) * 2010-09-03 2013-04-24 詹森药业有限公司 作为单酰甘油脂肪酶抑制剂的二-氮杂环丁烷二酰胺
CN105189482A (zh) 2013-02-07 2015-12-23 武田药品工业株式会社 作为毒蕈碱m4受体激动剂的哌啶-1-基羧酸酯和氮杂卓-1-基羧酸酯
AU2019247496A1 (en) * 2018-04-06 2020-10-22 Taro Pharmaceuticals Inc. Indene derivatives useful in treating pain and inflammation

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3066434D1 (en) 1979-11-21 1984-03-08 Kyowa Hakko Kogyo Kk Novel piperidine derivatives, method for the preparation thereof and pharmaceutical compositions containing them
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
ATE216580T1 (de) 1993-07-16 2002-05-15 Merck & Co Inc Benzoxazinon- und benzopyrimidinon- piperidinyl- verbindungen als tokolytische oxytocin-rezeptor- antagonisten
EP0786997A4 (en) * 1994-10-27 1998-03-11 Merck & Co Inc MUSCARINE ANTAGONISTS
AU7528696A (en) * 1995-10-31 1997-05-22 Merck & Co., Inc. Muscarine antagonists
US5756508A (en) * 1995-10-31 1998-05-26 Merck & Co., Inc. Muscarine antagonists
US5756497A (en) 1996-03-01 1998-05-26 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
AU721035C (en) 1996-09-10 2004-09-02 Dr. Karl Thomae Gmbh Modified aminoacids, pharmaceuticals containing these compounds and method for their production
JPH10158192A (ja) 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
SE9704546D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
WO1999032481A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
JP2000323278A (ja) 1999-05-14 2000-11-24 Toray Ind Inc 発光素子
ES2223588T3 (es) 1999-10-13 2005-03-01 Banyu Pharmaceutical Co., Ltd. Derivados de imidazolidinona sustituidos.
SE9904652D0 (sv) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
RU2317988C2 (ru) 2000-08-14 2008-02-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы, фармацевтическая композиция на их основе, применение фармацевтической композиции и способ ингибирования активности катепсина s
JP2002302675A (ja) 2001-04-06 2002-10-18 Fuji Photo Film Co Ltd 液晶組成物、それを用いた液晶素子およびアゾ化合物
BR0209129A (pt) 2001-04-18 2005-12-20 Euro Celtique Sa Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
PT1975164E (pt) 2001-04-18 2010-04-20 Euro Celtique Sa Compostos de octa-hidrobenzimidazolona utilizados como analgésicos
US7164024B2 (en) * 2001-04-20 2007-01-16 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
WO2003028650A2 (en) * 2001-10-02 2003-04-10 Acadia Pharmaceuticals, Inc. Benzimidazolidinone derivatives as muscarinic agents
EP1451173A4 (en) 2001-11-01 2005-10-26 Icagen Inc PIPERIDINE
DE60319813T2 (de) 2002-04-18 2009-04-23 Schering Corporation 1-(4-piperidinyl)benzimidazole als histamin h3 antagonisten
CA2488845A1 (en) * 2002-06-17 2003-12-24 Merck & Co., Inc. Opthalmic compositions containing selective m1 muscarinic agonists for treating ocular hypertension
JPWO2004069828A1 (ja) * 2003-02-04 2006-05-25 三菱ウェルファーマ株式会社 ピペリジン化合物およびその医薬用途
DE602004008762T2 (de) 2003-04-30 2008-06-12 The Institutes for Pharmaceutical Discovery, LLC, Branford Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen
US20050250794A1 (en) 2003-12-19 2005-11-10 Andrew Napper Methods of treating a disorder
US20050228023A1 (en) 2003-12-19 2005-10-13 Sri International Agonist and antagonist ligands of the nociceptin receptor
CA2568524A1 (en) * 2004-05-28 2005-12-15 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
NZ553696A (en) 2004-09-13 2010-02-26 Ono Pharmaceutical Co Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
AU2005289453A1 (en) 2004-09-27 2006-04-06 Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health Modulating MxA expression
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
WO2006130469A1 (en) 2005-05-27 2006-12-07 Oregon Health & Science University Stimulation of neurite outgrowth by small molecules
TW200815351A (en) 2006-05-02 2008-04-01 Astrazeneca Ab Novel compounds
TW200815405A (en) 2006-06-09 2008-04-01 Astrazeneca Ab Novel compounds
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
UY31672A1 (es) 2008-02-28 2009-09-30 "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación"
US20090221642A1 (en) 2008-03-03 2009-09-03 Astrazeneca Ab Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof-176
US20090275574A1 (en) 2008-05-05 2009-11-05 Astrazeneca Ab Novel compounds-300

Also Published As

Publication number Publication date
ECSP088966A (es) 2009-01-30
AU2007256012A1 (en) 2007-12-13
TW200813018A (en) 2008-03-16
RU2008147542A (ru) 2010-07-20
WO2007142583A1 (en) 2007-12-13
NO20085270L (no) 2009-01-07
JP2009539831A (ja) 2009-11-19
BRPI0712331A2 (pt) 2012-04-03
CA2654138A1 (en) 2007-12-13
SA07280303B1 (ar) 2011-02-23
EP2035411A1 (en) 2009-03-18
AR061305A1 (es) 2008-08-20
MX2008015136A (es) 2008-12-10
US20070287695A1 (en) 2007-12-13
US7956069B2 (en) 2011-06-07
CN101501025A (zh) 2009-08-05
KR20090018210A (ko) 2009-02-19
UY30397A1 (es) 2008-01-31

Similar Documents

Publication Publication Date Title
EP2035412A4 (en) MUSCARINIC RECEPTOR AGONISTS FOR THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA
ZA200808825B (en) Compounds that are agonists of muscarinic receptors and that may be effective in treating pain, alzheimer's disease and/or schizophrenia
IL264736B (en) Pharmaceutical preparations containing zonisamide for use in the treatment of diseases related to Alzheimer's disease
EP2091566A4 (en) COMBINATION THERAPIES AGAINST ALZHEIMER DISEASE AND SIMILAR ILLNESSES
EP2152318A4 (en) COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE
SI2104682T1 (sl) Diagnostika in zdravljenje Alzheimerjeve bolezni in drugih nevrodementnih bolezni
ZA201007460B (en) Use of epothelone in treating tau-associated disease including alzheimer's disease
EP2151435A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
IL185462A0 (en) New pharmaceutical compositions useful in the treatment of pain
PL1993365T3 (pl) Preparaty z biodostępnych kurkuminoidów do leczenia choroby alzheimera oraz innych zaburzeń powiązanych z wiekiem
IL219412A (en) Preparations containing Busimanden for use in the treatment of Alzheimer's or Alzheimer's disease
NO20085270L (no) Muscarin reseptoragonister som er effektive i behandling av smerte. Alzheimers sykdom og schizofreni
PT2083837E (pt) Utilização terapêutica de pelo menos uma neurotoxina botulínica no tratamento da dor induzida por, pelo menos, um agente anti-cancerígeno
PL1984357T3 (pl) Związki 2,4-pirymidynodiaminy do leczenia lub zapobiegania chorób autoimmunologicznych
IL177787A0 (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
IL185300A0 (en) New pharmaceutical compositions useful in the treatment of parkinson's disease
EP2320939A4 (en) TISSUE CALLICLE FOR THE TREATMENT OF PARKINSON DISEASE
IL195441A0 (en) Use of trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthaleneamine and its formamide in the preparation of medicaments for the treatment of pain disorders
EP2010215A4 (en) METHOD AND COMPOSITIONS FOR TREATING MORBUS CROHN
EP2285798A4 (en) AGONISTS OF MUSCARINIC RECEPTORS USEFUL IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA
EP2214488A4 (en) COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE AND RELATED DISORDERS
IL211957A0 (en) Composition for the use in the treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers
EP1954800A4 (en) COMPOSITION AND USE OF PHYTO-PERCOLATE FOR THE TREATMENT OF DISEASE
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
EP1928247A4 (en) COMPOSITION AND USE OF PHYTO-PERCOLATE FOR THE TREATMENT OF DISEASE